Designation of P2P Methyl Glycidic Acid as a List I Chemical
DEA finalizes designation of P2P methyl glycidic acid (BMK glycidic acid) and its esters, optical and geometric isomers as a List I chemical, imposing regulatory controls on handling, recordkeeping, and reporting.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Manufacturers, importers, exporters, and distributors of P2P methyl glycidic acid and its derivatives, including API and contract manufacturers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective 30 days after publication in the Federal Register (April 3, 2026), so by May 3, 2026.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The substance is now classified as a DEA List I chemical, subject to registration, recordkeeping, reporting, and security requirements under 21 CFR Parts 1309-1313.
Who it affects
Manufacturers, importers, exporters, and distributors of P2P methyl glycidic acid and its derivatives, including API and contract manufacturers.
What you must do
Review current operations involving this chemical; if not already registered as a List I chemical handler, apply for DEA registration; ensure compliance with recordkeeping and reporting obligations.
Deadline
Effective 30 days after publication in the Federal Register (April 3, 2026), so by May 3, 2026.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments
- Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
- Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
- Exempt Chemical Preparations Under the Controlled Substances Act
- Revision of Applications for Manufacturing and Procurement Quotas